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Nanoinformatics 2010 Workshop
GOAL (*in light of increasing data*):
“…determining which information is most 
relevant to the nanoscale science and 
engineering community.”
Hazard assessment studies of 
nanomaterials are proliferating
Source: http://icon.rice.edu/report.cfm
• How can we efficiently identify high quality
studies to meet our research needs?











Images from Albini et al 2010.  Nanomedicine. 6(2):277-88. 
Data quality/ 
presentation
What characteristics or 
criteria define a 
study as “high quality”?
Can we develop a tool that 
allows us to efficiently 
identify studies that meet 
these criteria?
Project Objective:
Develop a tool that uses Multi-Criteria 
Decision Analysis (MCDA) to identify 
studies that meet defined characteristics
• MCDA provides a framework to assist decision 
makers in choosing the best alternative from a 
range of alternatives amidst conflicting and 
competing criteria. 
• Can identify:
• Single most preferred option (study) or group of options 
(studies)
• Rank options
• Distinguish acceptable from unacceptable possibilities 
?
What will the MCDA tool do?
• Identify the “best” study (or studies) 
based on study criteria identified as 
important by the “stakeholders” 
(researchers, policy makers, etc.)
• Integrated with the Nanomaterial-





• Seek stakeholder input
• Develop test version of Tool
• Establish feasibility of concept
2. If proof-of-concept established, 
proceed with development
• Refine
• Program beta version of tool
• Integrate with databases
Initial Phase:  Specific steps
1. Identify stakeholders and goals
2. Identify criteria that define a 
“quality” study 
3. Build a decision framework
4. Rate studies based on criteria
5. Weight relative importance of 
criteria
6. Integrate results into test version
Identify stakeholders and goals
Image from http://blogbusinessworld.blogspot.com
• Who will use the tool?
• How will they use the information?
• What are their decision criteria for 
defining a study as useful/ not useful; 
high quality/ low quality?










response Data quality/ 
reliability












Particle size/ Distribution Protocol Protocol Persistence Peer review
Shape Cell line Species Mobility Independence
Composition Culture medium Age/ life stage Bioavailability Replicates
Surface chemistry Assay Gender Biomagnification Positive controls
Surface charge Concentration Exposure route Transformation Negative controls
Solubility/Dispersibility Protein binding Dose Variability
Aggregate/Agglomerate Time # of Subjects Error
Surface area/Specific 
surface area
Endpoint Target organ/ 
endpoint






Source: Oberdörster et al. 2005.  Particle and Fibre Toxicology. 2:8; ISO TC229. 
• Call to develop standardized characterization criteria 
for hazard identification of nanomaterials
• Which criteria are *most important*?
Establish relationships between 
























Weight the relative importance of 
criteria
Which do I consider more important…?
• Size distribution well characterized …or… 
better characterized surface chemistry?
• Standardized protocols…or…More 
replicates?
• Repeated dosing…or…Relevant exposure 
pathway?
Weight the relative importance of 
criteria













Use of controls 30
Descriptive statistics 20
Rate studies
• Mine databases of nanomaterial 
studies
Rate studies
Images from mavimo.org; 3dchem.com; esd.ornl.gov ; thorax.bmj.com; ocregister.com; mattk.com; 
opticsplanet.com; Oberdorster et al., 2005; topnews.in
Assessments may be factual or subjective
Rate studies
Subcriteria Study 1 Study 2 Study 3 Study 4
Size-distribution well-
characterized
5 3 2 1
Composition/ surface-coatings 
well-characterized
5 1 1 3
Highly pure 4 3 5 3
Relevant species 4 5 2 5
Relevant exposure route 2 5 3 3
Repeated exposure 3 5 2 1
Standard protocol 4 3 1 3
Use of controls 1 5 2 4
Descriptive statistics 2 3 2 4














S1 S2 S3 S4 S1 S2 S3 S4
Size-distribution well-
characterized
45 5 3 2 1 225 135 90 45
Composition/ surface-coatings 
well-characterized
40 5 1 1 3 200 40 40 120
Highly pure 10 4 3 5 3 40 30 50 30
Relevant species 25 4 5 2 5 100 125 50 125
Relevant exposure route 20 2 5 3 3 40 100 60 60
Repeated exposure 10 3 5 2 1 30 50 20 10
Standard protocol 25 4 3 1 3 100 75 25 75
Use of controls 30 1 5 2 4 30 150 60 120
Descriptive statistics 20 2 3 2 4 40 60 40 80
Totals 805 765 435 665
Moving forward…
• Determine stakeholder priorities and 
define key criteria
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